Q-omics provides the consensus-scored GGT5 profile across patient tissues and cancer cell-line models. GGT5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GGT5 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, GGT5 protein abundance shows 35,982 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KICH, and LSCC as cancer lineages where GGT5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGT5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGT5 survival associations across molecular data types. GGT5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGT5 RNA expression–survival associations across cancer types. High GGT5 expression shows unfavorable associations in KIRP, LGG and ACC, but favorable associations in THCA, SKCM and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for GGT5 RNA expression.
This table summarizes GGT5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GGT5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGT5 shows lower tumor expression in KICH, KIRP and UCEC and higher tumor expression in HNSC, LUAD and STAD. The KICH box plot shows higher GGT5 RNA expression in normal versus tumor tissue (log2 FC = −2.948, t-test p < 0.001).
This table shows molecular features associated with GGT5 in patient tissues and cancer cell lines. In patient samples, GGT5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GGT5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
